Drugs Containing Excipient (Inactive Ingredient) METHYLENE CHLORIDE

« Back to Dashboard

Branded drugs containing METHYLENE CHLORIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	ALLEGRA-D 24 HOUR	fexofenadine hydrochloride and pseudoephedrine hydrochloride	16590-852	METHYLENE CHLORIDE
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	METHYLENE CHLORIDE
Physicians Total Care Inc	ALLEGRA--D 24 HOUR	fexofenadine hydrochloride and pseudoephedrine hydrochloride	54868-5419	METHYLENE CHLORIDE

Generic drugs containing METHYLENE CHLORIDE excipient

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	atorvastatin calcium	0615-7769	METHYLENE CHLORIDE
NCS HealthCare of KY LLC dba Vangard Labs	metoprolol succinate	0615-7823	METHYLENE CHLORIDE
NCS HealthCare of KY LLC dba Vangard Labs	metoprolol succinate	0615-7825	METHYLENE CHLORIDE

Methylene Chloride Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 14, 2026

Methylene chloride, also called dichloromethane or DCM, is primarily a pharmaceutical process solvent rather than a conventional finished-dose excipient. Its pharmaceutical value comes from extraction, crystallization, granulation, coating, cleaning, and intermediate manufacturing. Demand remains tied to drug production volumes, but regulatory controls, worker-safety requirements, residual-solvent limits, and substitution by lower-risk solvents are constraining long-term growth.

The financial outlook is mixed: pharmaceutical demand is relatively resilient, while overall methylene chloride economics remain exposed to construction, coatings, adhesives, chemical manufacturing, and regional environmental policy. Suppliers with compliant closed-system production, solvent recovery, validated pharmaceutical grades, and replacement-solvent portfolios are positioned better than producers dependent on unrestricted commodity sales.

What is methylene chloride used for in pharmaceutical manufacturing?

Methylene chloride is a volatile chlorinated solvent with the chemical name dichloromethane and Chemical Abstracts Service number 75-09-2. Pharmaceutical applications include:

Application	Pharmaceutical role	Commercial implication
Extraction	Separates active ingredients, intermediates, and impurities	Demand depends on process chemistry and solvent recovery
Crystallization	Controls precipitation and solid-form isolation	Can be difficult to replace without changing process parameters
Reaction solvent	Supports selected synthetic reactions	Substitution may require process redevelopment
Granulation	Used in selected wet-granulation processes	Limited by residual-solvent controls
Film coating	Historically used in some coating systems	Increasingly replaced by aqueous or alcohol-based systems
Equipment cleaning	Removes organic residues	Subject to worker-exposure and emissions controls
Pharmaceutical intermediates	Used in chemical synthesis before final drug manufacture	Often represents greater volume than final-dose production

Methylene chloride is not generally intended to remain in the finished medicine. Under ICH Q3C, it is a Class 2 residual solvent with a permitted daily exposure of 6.0 mg per day and a concentration limit of 600 parts per million under the standard Option 1 calculation.[1]

The United States Pharmacopeia addresses residual methylene chloride under USP <467>, which establishes testing and acceptance requirements for residual organic solvents in drug substances, excipients, and drug products.[2]

How large is the pharmaceutical methylene chloride market?

A precise pharmaceutical-only market value is not publicly established. Producers typically report methylene chloride within broader chlor-alkali, solvents, specialty chemicals, or industrial chemicals segments. Pharmaceutical consumption is also difficult to isolate because drug manufacturers often purchase solvent through distributors or contract manufacturers.

The pharmaceutical segment is smaller than the total methylene chloride market, which includes paint removers, adhesives, metal cleaning, aerosols, chemical processing, and industrial extraction. Its commercial value is higher per unit than basic commodity demand when the product is supplied with:

• validated impurity specifications;
• controlled water and acidity levels;
• pharmaceutical-grade documentation;
• lot traceability;
• change-control support;
• residual-solvent certificates;
• regulatory audit records; and
• solvent-recovery compatibility.

Pharmaceutical demand is therefore best measured by qualified supply contracts and process usage rather than by reported global volume.

What drives demand for pharmaceutical methylene chloride?

Demand is linked to five factors:

1. Growth in generic and specialty-drug production.
2. Expansion of contract development and manufacturing organizations.
3. Continued use in complex small-molecule synthesis.
4. Regional availability of chloromethane feedstocks.
5. The cost and technical difficulty of replacing DCM in validated processes.

The strongest volume exposure is in small-molecule active pharmaceutical ingredient manufacturing. Biologics manufacturing has limited direct demand for methylene chloride because biologic processes rely more heavily on aqueous systems and do not use chlorinated solvents in the same way.

What is the financial trajectory for pharmaceutical methylene chloride?

The financial trajectory is likely to separate into three segments:

Segment	Outlook	Main financial driver
Commodity methylene chloride	Flat to declining in regulated markets	Environmental restrictions and substitution
Pharmaceutical-grade material	Stable to moderately growing	Qualification requirements and supply security
Solvent-management services	Growing faster than solvent volume	Recovery, recycling, compliance, and process redesign

Revenue growth in pharmaceutical methylene chloride can occur even if physical volume declines. Higher documentation costs, closed handling, packaging controls, testing, and supply-chain qualification can increase average selling prices. This is a compliance premium, not necessarily a sign of stronger underlying solvent consumption.

The main margin variables are chloromethane feedstock costs, electricity, freight, plant utilization, environmental compliance, packaging, and recovery economics. Methylene chloride is commonly produced from chloromethane intermediates, linking its economics to chlorine, methanol, energy, and regional chemical capacity.

Public companies generally do not disclose pharmaceutical methylene chloride revenue separately. Financial exposure must therefore be inferred from broader solvent or industrial-chemical segments.

Which companies supply methylene chloride for pharmaceutical use?

The global supply base includes large chlor-alkali and specialty-chemical producers, regional solvent manufacturers, and distributors. Relevant supplier groups include:

• Occidental Chemical;
• Olin;
• INEOS;
• AGC;
• Tosoh;
• Gujarat Alkalies and Chemicals;
• SRF;
• Chinese chloromethane producers;
• European chemical distributors; and
• pharmaceutical raw-material distributors supplying documented grades.

The supplier landscape is regional rather than fully global because methylene chloride is hazardous, volatile, and expensive to transport relative to its commodity value. Pharmaceutical buyers often qualify multiple manufacturing sites and distributors to reduce interruption risk.

The key competitive variables are not only price and purity. Buyers also evaluate plant location, regulatory status, batch consistency, packaging, transport classification, emergency response, technical support, and the supplier's ability to maintain supply during environmental or plant shutdowns.

What regulatory rules affect pharmaceutical methylene chloride?

United States EPA status

The U.S. Environmental Protection Agency issued a final TSCA risk-management rule for methylene chloride on April 30, 2024.[3] The rule prohibits several consumer and commercial uses, including paint and coating removal, while allowing certain industrial and commercial uses subject to workplace protections and other controls.

The rule does not create a blanket prohibition on every use of methylene chloride in pharmaceutical manufacturing. Pharmaceutical producers must assess whether their use falls within an allowed category and comply with applicable workplace, notification, recordkeeping, and exposure-control requirements.

The EPA rule creates several commercial effects:

• lower demand for prohibited consumer uses;
• higher compliance costs for permitted uses;
• increased demand for closed systems and engineering controls;
• potential supply consolidation;
• greater substitution pressure; and
• higher value for documented, compliant suppliers.

OSHA worker-exposure rules

OSHA's methylene chloride standard establishes an 8-hour permissible exposure limit of 25 parts per million and a short-term exposure limit of 125 parts per million.[4] Pharmaceutical facilities using open charging, sampling, cleaning, or transfer operations may need ventilation, respiratory protection, monitoring, medical surveillance, and written exposure-control programs.

These requirements increase the cost of using methylene chloride relative to solvents with less stringent occupational controls.

FDA and ICH residual-solvent requirements

FDA does not generally approve methylene chloride as a therapeutic ingredient. Its use is evaluated through the drug-substance, excipient, and drug-product manufacturing process. Sponsors must demonstrate that residual levels are controlled within applicable specifications.

ICH Q3C classifies methylene chloride as a Class 2 solvent because it presents a risk that requires limitation rather than routine unrestricted use.[1] Process changes involving DCM may require validation, impurity assessment, stability analysis, and regulatory documentation.

What are the main substitution risks?

Methylene chloride substitution is technically feasible in some applications but difficult in others. Candidate solvents include ethyl acetate, acetone, methyl ethyl ketone, heptane, ethanol, isopropanol, 2-methyltetrahydrofuran, and selected solvent blends.

Replacement option	Potential advantage	Main limitation
Ethyl acetate	Widely accepted and relatively familiar	Different polarity and boiling behavior
Acetone	Low cost and easy availability	More flammable and may alter selectivity
Ethanol or isopropanol	Common pharmaceutical solvents	Poor fit for some extraction and crystallization steps
2-Methyltetrahydrofuran	Useful in selected synthetic reactions	Higher cost and different regulatory profile
Heptane	Useful for nonpolar systems	Less effective for many polar compounds
Aqueous systems	Lower volatile-organic-solvent burden	May require major process and equipment changes

A substitute must meet more than a toxicity target. The manufacturer must evaluate yield, impurity profile, polymorph, particle size, residual solvent, drying time, flammability, equipment compatibility, recovery rate, and batch reproducibility.

This creates a two-speed market. Established processes may continue to use DCM because redevelopment carries technical and regulatory costs. New processes are more likely to avoid it, especially when sponsors are designing manufacturing routes with lower environmental and occupational risk.

How strong is the intellectual-property position for methylene chloride?

Methylene chloride itself is a mature commodity chemical and is not normally protected by meaningful composition-of-matter patents. Commercial defensibility usually comes from manufacturing know-how, plant economics, purification, closed-system handling, solvent recovery, packaging, and customer qualification.

Potentially relevant intellectual-property categories include:

• improved chloromethane production processes;
• catalysts and reaction conditions;
• purification and water-removal systems;
• pharmaceutical extraction processes;
• drug-specific crystallization methods;
• solvent-recovery systems;
• containment and transfer equipment; and
• formulations or coating systems that use DCM.

A pharmaceutical company may have a patent covering a drug manufacturing process that uses methylene chloride, but that does not create market exclusivity for the solvent itself. Patent risk is therefore generally low at the molecule level and higher at the process level.

What patent litigation, Paragraph IV challenges, and Orange Book issues apply?

Methylene chloride is not an FDA-approved drug product and is not ordinarily listed in the FDA Orange Book as an active pharmaceutical ingredient or finished dosage form. It therefore has no conventional Orange Book patent estate, no standalone Hatch-Waxman exclusivity period, and no ordinary Paragraph IV challenge directed to methylene chloride as an excipient.

Paragraph IV litigation may arise indirectly when a generic drug manufacturer challenges patents covering a drug process, formulation, or method of use in which methylene chloride is used during manufacture. That litigation concerns the drug product, not ownership of DCM.

Likewise, settlement agreements involving generic drugs may restrict manufacturing methods that use particular solvents, but these are product-specific arrangements and do not establish exclusivity for methylene chloride.

What manufacturing and supply-chain barriers affect the market?

The largest barriers are regulatory compliance and production infrastructure rather than patent rights.

Production concentration

Methylene chloride supply depends on chloromethane capacity, chlorine availability, methanol economics, energy prices, and regional chemical manufacturing. A plant outage can affect pharmaceutical buyers even when global capacity appears sufficient.

Transport and storage

DCM is volatile and hazardous. Transport, storage, container selection, worker exposure, and emergency response add cost. Pharmaceutical buyers may prefer regional inventory or distributor-held safety stock.

Qualification requirements

Changing suppliers can require:

• vendor qualification;
• comparative impurity testing;
• process compatibility studies;
• updated quality agreements;
• stability or validation review;
• change-control approval; and
• regulatory assessment.

These switching costs support incumbent suppliers after qualification.

Solvent recovery

Large pharmaceutical plants can reduce purchases through distillation and recycling. Recovery lowers net solvent demand but raises demand for recovery equipment, analytical controls, waste management, and technical services.

How does methylene chloride compare with other pharmaceutical solvents?

Methylene chloride has a low boiling point of about 39.6°C and strong solvency. These characteristics make it useful for rapid evaporation and selective extraction. Its disadvantages are toxicity concerns, occupational exposure controls, environmental regulation, and residual-solvent limitations.

Criterion	Methylene chloride	Ethyl acetate	Acetone	Ethanol
Boiling point	Low	Moderate	Low	Moderate
Flammability	Limited relative to many organic solvents	High	High	High
ICH category	Class 2	Class 3	Class 3	Class 3
Solvency profile	Strong, relatively nonpolar	Moderate	Polar aprotic	Polar protic
Substitution ease	Process-dependent	Often practical	Often practical	Highly process-dependent
Regulatory pressure	High	Lower	Lower	Lower

The comparison favors alternative solvents for new process development. DCM retains an advantage where its physical properties deliver better selectivity, faster drying, higher yield, or simpler crystallization.

What generic launch and biosimilar risks exist?

Generic drug manufacturing creates the largest direct pharmaceutical demand base for methylene chloride because generic API production emphasizes cost, yield, and established chemistry. However, generic manufacturers also face strong pressure to reduce hazardous solvent use because of workplace rules, customer audits, and environmental procurement standards.

Biosimilar risk is limited. Biologics generally do not consume methylene chloride at the same rate as small-molecule API operations. Biosimilar market growth therefore does not materially offset potential DCM substitution in small-molecule manufacturing.

The main commercial risk is process conversion, not patent expiry. When a drug process is redesigned to eliminate DCM, solvent demand can disappear even if the drug remains commercially successful.

What is the geographic outlook?

North America

The United States has the strongest near-term regulatory pressure because of the EPA TSCA rule and OSHA exposure requirements. Demand will shift toward compliant industrial uses, closed systems, and documented supply.

Europe

European chemical regulation and pharmaceutical environmental standards favor substitution and emissions reduction. Pharmaceutical use may continue where technical performance justifies it, but new process development is likely to prefer lower-risk alternatives.

China and India

China and India remain important production and consumption centers for pharmaceutical intermediates and APIs. Their demand is supported by manufacturing scale and cost advantages, but export-oriented suppliers increasingly face customer requirements based on U.S. and European solvent controls.

Japan and South Korea

These markets place emphasis on high-purity chemical supply, reliable documentation, and process consistency. Specialty-grade and pharmaceutical-qualified products are more defensible than undifferentiated commodity supply.

What is the investment outlook for methylene chloride suppliers?

The investment case is defensive rather than high growth.

Positive factors include:

• recurring demand from established API processes;
• high switching costs after pharmaceutical qualification;
• supply-chain value from regional inventory;
• premium pricing for documented grades;
• growth in solvent recovery and compliance services; and
• resilience of global drug production.

Negative factors include:

• substitution in new pharmaceutical processes;
• EPA and European regulatory restrictions;
• worker-protection costs;
• commodity price volatility;
• limited pharmaceutical revenue disclosure;
• dependence on nonpharmaceutical end markets; and
• potential plant shutdowns or supply interruptions.

The strongest financial position belongs to suppliers that combine commodity production with pharmaceutical documentation, solvent recovery, regional distribution, and alternative-solvent offerings. Pure commodity exposure has weaker long-term pricing power.

Key Takeaways

• Methylene chloride is mainly a pharmaceutical process solvent, not a conventional finished-dose excipient.
• It is an ICH Q3C Class 2 residual solvent with a 6.0 mg/day permitted daily exposure and a 600 ppm Option 1 concentration limit.
• Pharmaceutical-only market size and revenue are not separately disclosed by most producers.
• Volume growth is constrained by substitution, but qualified pharmaceutical-grade supply can earn a compliance premium.
• The U.S. EPA's 2024 TSCA rule increases regulatory and operational costs without creating a universal ban on pharmaceutical manufacturing use.
• Patent, Orange Book, and Paragraph IV risks are generally indirect and product-specific.
• Biosimilar growth has limited impact because biologic manufacturing uses less methylene chloride than small-molecule API production.
• The most durable commercial opportunities are compliant supply, closed handling, recovery systems, and replacement-solvent development.

FAQs

Is methylene chloride an approved pharmaceutical excipient?

Methylene chloride is generally used as a process solvent rather than an intentional excipient in the final dosage form. Its residual presence must comply with applicable ICH Q3C, USP <467>, and product-specific quality requirements.

What is the permitted residual methylene chloride limit in pharmaceuticals?

ICH Q3C lists a 6.0 mg/day permitted daily exposure and a 600 ppm concentration limit under Option 1, subject to the applicable drug-product calculation and regulatory controls.[1]

Will the EPA ban pharmaceutical use of methylene chloride?

The 2024 EPA TSCA rule bans or restricts specified uses but does not create a universal prohibition on all pharmaceutical manufacturing applications. Permitted uses remain subject to workplace and operational controls.[3]

Is methylene chloride more profitable than ethanol for pharmaceutical suppliers?

Methylene chloride can command a higher compliance and documentation premium, but ethanol has a broader pharmaceutical acceptance profile and lower regulatory friction. Relative profitability depends on feedstock costs, recovery, packaging, and customer qualification.

Can a pharmaceutical manufacturer switch from methylene chloride without changing its regulatory filing?

Usually not automatically. A solvent change can affect impurities, yield, polymorph, particle properties, drying, residual solvents, and validation. The required regulatory action depends on the process, product, filing category, and material impact.

References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2021). Q3C(R8): Impurities: Guideline for residual solvents. ICH.

2. United States Pharmacopeia. (2024). General chapter <467>: Residual solvents. U.S. Pharmacopeial Convention.

3. U.S. Environmental Protection Agency. (2024, April 30). Methylene chloride; regulation under the Toxic Substances Control Act. Federal Register.

4. Occupational Safety and Health Administration. (n.d.). 29 C.F.R. § 1910.1052: Methylene chloride. U.S. Department of Labor.